XML 26 R14.htm IDEA: XBRL DOCUMENT v3.24.2.u1
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION
 6 Months Ended
Jun. 30, 2024
Concentration Risk And Geographic Information [Abstract]  
REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION REVENUE, CREDIT CONCENTRATIONS AND GEOGRAPHIC INFORMATION
The Company operates in one business segment, which focuses on the development and commercialization of innovative therapies for people with serious and life-threatening rare diseases and medical conditions.
The following table presents Total Revenues and disaggregates Net Product Revenues by product.
Three Months Ended
June 30,		Six Months Ended
June 30,
2024202320242023
VOXZOGO$183,923 $113,337 $336,812 $201,173 
VIMIZIM178,016 177,392 370,536 366,584 
NAGLAZYME132,049 90,103 237,678 213,124 
PALYNZIQ88,291 74,868 164,000 137,220 
BRINEURA45,309 38,058 84,356 77,202 
ALDURAZYME38,558 40,318 73,820 74,721 
KUVAN28,551 50,622 64,461 101,100 
ROCTAVIAN7,432 — 8,281 — 
Total net product revenues702,129 584,698 1,339,944 1,171,124 
Royalty and other revenues9,900 10,577 20,918 20,566 
Total revenues$712,029 $595,275 $1,360,862 $1,191,690 
The Company considers there to be revenue concentration risks for regions where Net Product Revenues exceed 10% of consolidated Net Product Revenues. The concentration of the Company’s Net Product Revenues within the regions below may have a material adverse effect on the Company’s revenues and results of operations if sales in the respective regions experience difficulties. The table below disaggregates total Net Product Revenues by geographic region, which is based on patient location for the Company's commercial products sold directly by the Company, except for ALDURAZYME, which is marketed and sold exclusively by Sanofi worldwide.
Three Months Ended
June 30,		Six Months Ended
June 30,
2024202320242023
United States$227,449 $191,655 $420,448 $358,439 
Europe220,990 183,434 416,738 344,126 
Latin America84,418 75,444 163,012 143,192 
Middle East49,701 25,630 106,776 117,272 
Rest of world81,013 68,217 159,150 133,374 
Total net product revenues marketed by the Company$663,571 $544,380 $1,266,124 $1,096,403 
ALDURAZYME net product revenues marketed by Sanofi38,558 40,318 73,820 74,721 
Total net product revenues$702,129 $584,698 $1,339,944 $1,171,124 
The following table illustrates the percentage of the Company’s total Net Product Revenues attributed to the Company’s largest customers for the periods presented.
Three Months Ended
June 30,		Six Months Ended
June 30,
2024202320242023
Customer A14 %15 %14 %15 %
Customer B11 %12 %11 %11 %
Customer C10 %10 %9 %9 %
Total35 %37 %34 %35 %
On a consolidated basis, three customers accounted for 15%, 12%, and 10% of the Company’s June 30, 2024 accounts receivable balance, respectively, compared to December 31, 2023, when two customers accounted for 15% and 12% of the accounts receivable balance, respectively. As of June 30, 2024, and December 31, 2023, the accounts receivable balance for Sanofi included $67.1 million and $63.4 million, respectively, of unbilled accounts receivable, which becomes payable to the Company when the product is sold through by Sanofi. The Company does not require collateral from its customers, but does perform periodic credit evaluations of its customers’ financial condition and requires prepayments in certain circumstances.
The Company is mindful that conditions in the current macroeconomic environment, such as inflation, changes in interest and foreign currency exchange rates, natural disasters, geopolitical instability, and supply chain disruptions, could affect the Company’s ability to achieve its goals. In addition, the Company sells its products in countries that face economic volatility and weakness. Although the Company has historically collected receivables from customers in certain countries, sustained weakness or further deterioration of the local economies and currencies may cause customers in those countries to delay payment or be unable to pay for the Company’s products. The Company believes that the allowances for doubtful accounts related to these countries, if any, are adequate based on its analysis of the specific business circumstances and expectations of collection for each of the underlying accounts in these countries. The Company will continue to monitor these conditions and will attempt to adjust its business processes, as appropriate, to mitigate macroeconomic risks to its business.